Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis
Introduction A major development in solid malignancy treatment is the application of immune checkpoint inhibitors (ICIs), which have produced durable responses and increased survival rates. However, the therapeutic effect of ICIs has great heterogeneity in patients with cancer. We propose a systemat...
Saved in:
Main Authors: | Xiaoguang Yang, Yunming Li, Xuemei Xiang, Wang Guo, Pengfei Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-08-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/8/e058692.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Titin gene mutations enhance radiotherapy efficacy via modulation of tumour immune microenvironment in rectum adenocarcinoma
by: Hengchang Liu, et al.
Published: (2025-01-01) -
Giant Malignant Phyllodes Tumour of Breast
by: Ramakrishnan Krishnamoorthy, et al.
Published: (2014-01-01) -
Association of tumour mutation burden with prognosis and its clinical significance in stage III gastric cancer
by: Ya-Lin Han, et al.
Published: (2024-11-01) -
The regulatory roles of RNA-binding proteins in the tumour immune microenvironment of gastrointestinal malignancies
by: Dongqi Li, et al.
Published: (2025-12-01) -
Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
by: Ming Zheng
Published: (2022-01-01)